YOLFTbeta
65

Lumosa Therapeutics Co. Ltd.

6535 · TWO · Healthcare / Biotechnology

85.10TWD+7.70 (+9.95%)

Price History

Full chart

Market Stats

Previous Close77.40
Open78.90
Day Range78.40 – 85.10
52-Week Range73.70 – 319.50
Volume682.71K
Market Cap14.24B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.24
Dividend Yield0.00%
Beta0.09
50-Day Avg82.34
200-Day Avg128.21

About

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-clinical stage for the treatment of solid tumors. In addition, the company engages in the investment, new drug development consulting, and service and transfer of techniques activities. The company was formerly known as SunTen Phytotech Co., Ltd. and changed its name to Lumosa Therapeutics Co., Ltd. in June 2014. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOSheng Wen Yeh
  • Employees36
  • HeadquartersNo. 3-2, Park Street, Taipei, Taiwan, 11503, Taiwan
  • Websitehttps://www.lumosa.com.tw

Leadership

  • Sheng Wen YehGeneral Manager
  • Li Fang PanChief Financial Officer and Manager of the Administrative Office
  • Pei-Jiun ChenChief Operating Officer
  • Lan Ying HuangAccounting Supervisor

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue172.04M21.65M17.36M26.64M56.92M39.15M35.83M
Growth (%)--87.42%-19.81%+53.45%+113.63%-31.21%-8.49%
Cost of Revenue67.22M8.49M7.47M12.08M15.44M21.44M13.96M
Gross Profit104.83M13.16M9.89M14.56M41.48M17.71M21.87M
Gross Margin60.93%60.77%56.96%54.65%72.88%45.24%61.04%
Operating Expense254.79M335.57M-86.32M518.86M291.37M374.66M355.38M
Operating Income-149.96M-322.41M96.21M-504.30M-249.89M-356.94M-333.50M
Operating Margin-87.17%-1489.14%554.12%-1892.86%-439.05%-911.64%-930.77%
EBITDA-110.63M-286.79M128.31M-482.13M-226.53M-428.24M-335.16M
EBITDA Margin-64.30%-1324.59%739.02%-1809.67%-398.00%-1093.72%-935.39%
Net Income-240.94M-322.56M95.95M-494.66M-238.04M-424.78M-340.54M
Net Income Margin-140.04%-1489.83%552.62%-1856.70%-418.23%-1084.91%-950.41%
R&D212.19M317.04M406.05M280.46M369.30M322.86M304.37M
R&D as % of Total Revenue123.33%1464.34%2338.70%1052.69%648.86%824.58%849.46%
Interest Expense271.00K151.00K260.00K149.00K47.00K187.00K201.00K
Interest Expense % of Total Revenue0.16%0.70%1.50%0.56%0.08%0.48%0.56%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.32B1.78B2.35B1.89B1.66B2.13B1.65B
Total Liabilities278.44M201.63M230.11M215.72M227.69M205.46M131.04M
Total Equity1.05B1.58B2.12B1.63B1.40B1.91B1.51B
Cash168.80M898.64M840.32M516.85M425.25M235.49M181.59M
Total Debt11.71M16.95M11.49M4.69M12.61M--
Net Debt-157.09M-881.69M-828.83M-512.16M-412.64M--

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-379.52M-129.11M-452.60M-300.46M-328.21M-296.33M-360.50M
Financing Cash Flow7.33M852.58M431.28M46.17M-3.94M--
Capital Expenditure0680.00K576.00K2.29M15.02M450.00K668.00K
Free Cash Flow-379.52M-129.79M-453.18M-302.74M-343.23M-296.78M-361.16M
FCF to OCF100.00%100.53%100.13%100.76%104.58%100.15%100.19%

Earnings

Report DateNov 13, 2016Mar 31, 2017May 12, 2017Nov 7, 2021Mar 3, 2022May 14, 2024Aug 8, 2024Nov 11, 2024Mar 11, 2025May 5, 2025Aug 7, 2025Nov 12, 2025Feb 23, 2026May 11, 2026
EPS Estimate-0.75-0.78-0.78-0.49-0.78-0.61-0.73-0.64-0.45-0.48-0.46-0.48-0.51-0.63
EPS Actual-0.87-0.62-0.623.10-2.18-0.710.41-1.40-0.90-0.63-0.89-0.20-0.340.00
Surprise-16.00%20.51%20.51%732.65%-179.49%-16.39%156.16%-118.75%-100.00%-31.25%-93.48%58.33%33.33%100.00%
TimingAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap14.24B
Enterprise Value13.15B
Trailing P/E0.00
Forward P/E0.00
Price / Sales414.24
Price / Book11.13
EPS-2.24
Book Value7.39
Revenue (TTM)34.37M
Gross Profit (TTM)18.27M
EBITDA-299.21M
Profit Margin0.00%
Operating Margin-2359.56%
Return on Equity-26.11%
Return on Assets-12.15%
Shares Outstanding167.49M
Shares Float89.47M
Beta0.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%